Finance and funding issues affecting the biotechnology industry appear to be something of a chicken and egg scenario. [ + ]

The need to build Victoria's biotechnology infrastructure base has been recognised through the establishment of the Biotechnology Platform Technology Working Party. [ + ]

Had Amrad Corporation been conceived in the United States it would only now be considering a public listing, according to its managing director. [ + ]

While Victorian companies who have been around the block a few times reckon the latest batch of biotech newcomers have got it relatively easy, the feeling out there is quite different. [ + ]

One word is consistently on people's lips when discussing Victoria's biotechnology scene: hub. [ + ]

Venture capitalists need to be as a good at analysing their clients as any psychiatrist, says Dr Mike Hirshorn, a medical doctor turned venture capitalist, now with Sydney-based VC Nanyang Ventures. [ + ]

Dr Graham Mitchell is in a unique position to comment on biotechnology in Victoria. As one of the four scientists in biotech consultancy Foursight Associates, he is one of the chief scientific advisers to the Victorian government. [ + ]

With years of experience in the business of science and training as a scientist as well as in business management, Cerylid Biosciences CEO Dr Jackie Fairley is well equipped to give advice on the pitch, whether it's in the elevator or at a venture capital forum. [ + ]

It used to be that biology students would run a mile from anything that smacked of computing. Now, with bio-IT touted as an indispensable element of the life sciences, what's changed? [ + ]

You can't pick up a general article about proteomics without reading somewhere in the story: "The word 'proteomics' was coined by Marc Wilkins, then a PhD student in Keith Williams' lab at Macquarie University in 1994..." [ + ]

The NSW government launched its BioFirst program in September last year. Like most other governments' biotech programs, the NSW initiative involves several government departments. [ + ]

Biotech in NSW doesn't appear to depend on fancy government packages, but new infrastructures are changing the face of bio in the First State. [ + ]

In the last month, three of Australia's most experienced listed biotechs have endured roller coaster rides on the stock market, in the case of all three because of upheaval at the board level. [ + ]

Just over a month ago, with his company on the verge of big new international deals, Peptech managing director Stephen Kwik agreed to leave the company so the board could replace him with a CEO with scientific background and commercial expertise. [ + ]

Scientist-turned-financier Dr Kevin Healey is one of an elite group which has used its life science credentials as a springboard to make a splash as venture capitalists. [ + ]